Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 2 of 18
Next
>>
>
26 to 50 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
BT-20	CAL-101	2	72	flat	flat	BT20 idelalisib 0 2 72	8	1.768	Inf	0.818	0.0943	0.818	0.01	0.226	0.463	0.898	Inf	0.845	0.918	0.845	0.01	0.222	0.471	0.912
HCC70	Alpelisib	2	72	flat	flat	HCC70 alpelisib 0 2 72	8	1.799	Inf	0.748	0.0777	0.748	0.01	0.00864	0.974	0.907	Inf	0.785	0.932	0.785	0.01	0.00534	0.984	0.919
HCC1806	Alpelisib	1	72	flat	flat	HCC1806 alpelisib 0 1 72	8	2.771	Inf	0.918	0.0583	0.918	0.01	-0.337	1.0	0.94	Inf	0.891	0.921	0.891	0.01	-0.351	1.0	0.919
HCC1806	Alpelisib	2	72	flat	flat	HCC1806 alpelisib 0 2 72	8	2.856	Inf	0.921	0.0566	0.921	0.01	-0.336	1.0	0.941	Inf	0.891	0.921	0.891	0.01	-0.351	1.0	0.919
HCC1806	Alpelisib	3	72	flat	flat	HCC1806 alpelisib 0 3 72	8	3.224	Inf	0.93	0.0502	0.93	0.01	-0.335	1.0	0.948	Inf	0.891	0.921	0.891	0.01	-0.351	1.0	0.919
BT-20	KIN001-244	3	72	flat	flat	BT20 KIN001-244 0 3 72	8	2.608	Inf	0.841	0.062	0.841	0.01	0.489	0.133	0.935	Inf	0.805	0.922	0.805	0.01	0.475	0.145	0.919
HCC38	Alpelisib	3	72	flat	flat	HCC38 alpelisib 0 3 72	8	1.398	Inf	0.75	0.0995	0.75	0.01	0.141	0.634	0.883	Inf	0.829	0.932	0.829	0.01	0.113	0.698	0.92
BT-20	XL147	2	72	flat	flat	BT20 pilaralisib 0 2 72	8	1.784	Inf	0.759	0.073	0.759	0.01	-0.0058	1.0	0.907	Inf	0.796	0.937	0.796	0.01	-0.00637	1.0	0.92
HCC38	Alpelisib	1	72	flat	flat	HCC38 alpelisib 0 1 72	8	1.738	Inf	0.757	0.0835	0.757	0.01	0.593	0.0674	0.909	Inf	0.798	0.929	0.798	0.01	0.579	0.0744	0.923
BT-549	Alpelisib	1	72	flat	flat	BT549 alpelisib 0 1 72	8	1.822	Inf	0.747	0.0781	0.747	0.01	0.439	0.176	0.914	Inf	0.782	0.931	0.782	0.01	0.415	0.2	0.925
BT-549	Alpelisib	3	72	flat	flat	BT549 alpelisib 0 3 72	8	1.743	Inf	0.817	0.068	0.817	0.01	-0.0192	1.0	0.915	Inf	0.846	0.942	0.846	0.01	-0.0162	1.0	0.928
BT-20	CAL-101	3	72	flat	flat	BT20 idelalisib 0 3 72	8	2.589	Inf	0.916	0.0535	0.916	0.01	0.0547	0.845	0.944	Inf	0.894	0.932	0.894	0.01	0.0506	0.856	0.929
HCC38	Alpelisib	2	72	flat	flat	HCC38 alpelisib 0 2 72	8	2.086	Inf	0.848	0.0559	0.848	0.01	-0.0371	1.0	0.931	Inf	0.848	0.944	0.848	0.01	-0.0359	1.0	0.932
BT-20	CAL-101	1	72	flat	flat	BT20 idelalisib 0 1 72	8	2.112	Inf	0.869	0.0546	0.869	0.01	0.0807	0.777	0.938	Inf	0.867	0.943	0.867	0.01	0.0778	0.784	0.936
BT-20	XL147	1	72	flat	flat	BT20 pilaralisib 0 1 72	8	2.128	Inf	0.815	0.048	0.815	0.01	0.411	0.205	0.939	Inf	0.813	0.95	0.813	0.01	0.383	0.234	0.937
HCC38	KIN001-244	3	72	flat	flat	HCC38 KIN001-244 0 3 72	8	1.472	Inf	0.849	0.0658	0.849	0.01	0.182	0.548	0.929	Inf	0.891	0.952	0.891	0.01	0.181	0.549	0.948
BT-549	AS605240	2	72	flat	flat	BT549 AS-605240 0 2 72	8	1.961	Inf	0.91	0.0479	0.91	0.01	0.414	0.201	0.949	Inf	0.914	0.954	0.914	0.01	0.418	0.197	0.951
HCC70	Alpelisib	3	72	flat	flat	HCC70 alpelisib 0 3 72	8	2.465	Inf	0.859	0.027	0.859	0.01	0.407	0.209	0.961	Inf	0.835	0.968	0.835	0.01	0.394	0.222	0.954
BT-20	KIN001-244	1	72	flat	flat	BT20 KIN001-244 0 1 72	8	2.125	Inf	0.911	0.0401	0.911	0.01	-0.00641	1.0	0.957	Inf	0.908	0.958	0.908	0.01	-0.00745	1.0	0.955
BT-20	TGX221	2	72	flat	flat	BT20 TGX-221 0 2 72	8	1.656	Inf	1.0	0.0477	1.0	0.01	-0.101	1.0	0.946	Inf	1.0	0.961	1.0	0.01	-0.101	1.0	0.956
BT-549	XL147	1	72	flat	flat	BT549 pilaralisib 0 1 72	8	1.855	Inf	0.941	0.0385	0.941	0.01	-0.0931	1.0	0.954	Inf	0.946	0.965	0.946	0.01	-0.0808	1.0	0.958
HCC70	KIN001-244	3	72	flat	flat	HCC70 KIN001-244 0 3 72	8	2.472	Inf	0.916	0.0295	0.916	0.01	-0.0208	1.0	0.969	Inf	0.899	0.965	0.899	0.01	-0.00883	1.0	0.963
HCC38	XL147	2	72	flat	flat	HCC38 pilaralisib 0 2 72	8	2.194	Inf	0.938	0.0288	0.938	0.01	-0.0925	1.0	0.968	Inf	0.933	0.969	0.933	0.01	-0.0418	1.0	0.965
HCC38	KIN001-244	2	72	flat	flat	HCC38 KIN001-244 0 2 72	8	2.210	Inf	0.948	0.0304	0.948	0.01	-0.0213	1.0	0.969	Inf	0.944	0.967	0.944	0.01	-0.0218	1.0	0.966
BT-549	XL147	3	72	flat	flat	BT549 pilaralisib 0 3 72	8	1.772	Inf	0.933	0.0351	0.933	0.01	-0.0699	1.0	0.962	Inf	0.941	0.969	0.941	0.01	-0.0712	1.0	0.967

|<
<<
Previous
Page 2 of 18
Next
>>
>
26 to 50 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)